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suggest that this strategy should be considered as therapy before proceeding with 
surgical nephrectomy.
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1  | INTRODUCTION
Nephrotic	syndrome	is	a	glomerular	disorder	that	is	defined	by	mas-
sive	 proteinuria,	 hypoalbuminemia,	 and	 general	 edema.	 Children	
with nephrotic syndrome mostly respond well to steroids and have 
a	favorable	prognosis.	In	contrast,	therapy-resistant	nephrotic	syn-
drome	generally	results	in	ESRD	within	a	few	years.1,2
Kidney transplantation in patients with active nephrotic syndrome 
poses	2	major	 risks.	First	of	all,	hypoalbuminemia	 leads	 to	an	unfa-
vorable circulatory status and an increased risk of thromboembolic 
events,	both	resulting	in	major	risks	for	the	renal	transplant.3,4	In	fact,	
optimal hydration is the most important perioperative intervention to 
ensure graft function.5	Second,	nephrotic	syndrome	may	relapse	after	
transplantation.	Early	detection	of	proteinuria	after	transplantation	is	
vital to start treatment for such relapses in order to improve prog-
nosis. “Contamination” of the urine with proteinuria from the native 
kidneys	may	 hinder	 such	 early	 detection.	 Furthermore,	 proteinuria	
may	also	indicate	rejection	of	the	transplant	kidney,	for	which	prompt	
diagnosis and treatment are also necessary.6 Ponticelli et al have 
shown that renal survival rates of patients with proteinuria are worse 
in	comparison	with	non-proteinuric	patients.7	In	fact,	the	quantity	of	
proteinuria is a reliable predictor of the allograft outcome.7
In	order	to	improve	the	circulatory	status	during	and	after	renal	
transplantation and allow for early detection of proteinuria of the 
transplant	kidney,	treatment	to	stop	the	native	proteinuria	is	often	
needed.	Currently,	the	treatment	of	choice	in	such	patients	is	surgi-
cal nephrectomy.2,8 This leads to at least one additional operation in 
these	patients,	which	is	known	to	have	high	rates	of	morbidity	and	
even mortality (up to 2.0%).9,10	A	less	invasive	but	successful	therapy	
is	 bilateral	 renal	 artery	 embolization,	which	may	 have	 severe	 side	
effects,	 such	 as	 severe	 flank	 pain	 and	 fever,	 and	 requires	 specific	
interventional skills that may not be readily available.11-13
ACE	inhibitors	and	NSAIDs	have	antiproteinuric	effects	and	are	










artery	 embolization	 in	order	 to	 achieve	medical	 nephrectomy	 in	 a	
safe	non-invasive	way	in	patients	with	persistent	severe	proteinuria	




syndrome	 in	 the	 period	 2013-2018.	 This	 period	 was	 chosen	 for	
reasons	of	data	availability	in	the	digital	hospital	data	system.	Of	these	
patients,	we	 identified	 those	who	were	 treated	with	medication	 in	
order to induce a medical nephrectomy prior to renal transplantation. 
Such	patients	received	an	ACE	inhibitor	and/or	NSAID	after	starting	
dialysis. The dosage of the medication was based on body weight and 
blood	pressure,	and	adjusted	based	on	the	anti-diuretic	effect,	blood	
pressure,	and	side	effects	such	as	liver	function	tests.	In	all	cases,	the	









the start of the medical nephrectomy.
2.1 | Statistical analysis






pared for renal transplantation were identified in this study. Three 
patients	were	 not	 started	 on	ACE	 inhibitors	 for	medical	 nephrec-
tomy,	 because	 of	 severe	 illness	 (N	=	 1,	 surgical	 nephrectomy	was	
performed	to	stabilize	the	patient	due	to	extensive	fluid	overload)	
and	therapy-resistant	malignant	hypertension	(N	=	2).	Eight	patients	
did receive medication to induce a medical nephrectomy prior to 
renal	 transplantation	 (Figure	1	and	Table	1).	The	diagnosis	 leading	
to	ESRD	was	CNS	due	to	a	mutation	in	the	NPHS1	gene	(n	=	2)	or	
NPHS2	gene	(n	=	3),	and	FSGS	without	a	proven	genetic	basis	(n	=	3).	
All	 patients	 were	 on	 dialysis	 prior	 to	 the	 kidney	 transplantation,	
whereof 4 patients on hemodialysis and 4 on peritoneal dialysis.
Table	1	 shows	 the	demographics,	 preoperative	 characteristics,	
and	post-operative	outcome	of	 these	patients.	The	median	 age	 at	
transplantation	was	5.7	(range	3.4-10.0)	years	with	a	median	age	of	




without recurrence of nephrotic syndrome despite keeping their na-
tive	kidneys.	One	patient	was	still	on	hemodialysis	waiting	for	kidney	
transplantation,	and	1	patient	had	a	therapy-resistant	recurrence	of	
the disease after transplantation and had to restart dialysis.
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3.2 | Medical nephrectomy
Figure	1	shows	a	flow	diagram	of	the	medication	used	for	medical	
nephrectomy in our patients. The medication dosages are presented 
in	Table	1.	All	eight	patients	received	enalapril	with	a	median	daily	
starting	dose	of	0.09	mg/kg	(range	0.07-0.31	mg/kg).	Adjustments	in	
dosage were made based on blood pressure and urine output in the 
individual	patients,	with	a	median	maximum	daily	dose	of	0.30	mg/
kg	(range	0.03-0.76	mg/kg).	Reasons	to	lower	or	stop	enalapril	were	
hypotension or persistent significant urine output despite increases 
in the dose. Two patients received indomethacin (1.0 and 2.0 mg/
kg/day,	respectively)	after	unsuccessful	medical	nephrectomy	with	
enalapril:	Patient	3	was	taken	off	enalapril	after	2.5	months	for	hy-
potension,	 after	 which	 indomethacin	 was	 started;	 patient	 8	 was	
treated with enalapril for 14 months when indomethacin was added. 
In	both	patients,	medical	nephrectomy	with	indomethacin	had	to	be	
stopped	due	 to	 elevated	 transaminases	 after	 1	 and	6	months,	 re-
spectively.	 In	1	patient,	diclofenac	was	added	to	enalapril	because	
of persistent proteinuria and significant urine output despite an ac-
ceptable	serum	albumin	level	of	34	g/L.	It	was	started	at	a	dose	of	
50	mg	3	times	a	week	after	the	hemodialysis	session	and	increased	
to 100 mg 3 times a week.
Albumin	levels	increased	or	stayed	in	within	normal	range	in	all	




who received diclofenac in addition to enalapril showed no change 
in	serum	albumin	levels,	as	the	albumin	level	before	start	was	already	
34	g/L.
In	 all	 patients,	 the	 medication	 for	 medical	 nephrectomy	 was	
stopped at least 1 day before kidney transplantation.
In	 6	 patients,	medical	 nephrectomy	prior	 to	 renal	 transplanta-
tion	 was	 successful.	 In	 two	 patients,	 treatment	 was	 unsuccessful	
and surgical bilateral nephrectomy was performed as preparation 
for	renal	transplantation.	Both	these	patients	were	diagnosed	with	
NPHS1	mutations.	In	1	patient,	medical	nephrectomy	failed	because	
of side effects (enalapril because of hypotension and indomethacin 
because of elevated transaminases). The other patient had no rel-
evant change in urine output and proteinuria despite enalapril and 
indomethacin,	and	medication	dose	could	not	be	increased	because	
of a low blood pressure and a slight increase in liver function tests.
3.3 | Side effects
The	only	side	effect	of	enalapril	seen	was	hypotension.	In	3	cases,	




effect,	 leading	 to	 cessation	 of	 treatment	 and	 subsequent	 surgical	
bilateral	nephrectomy.	In	contrast,	there	were	no	side	effects	seen	




nephrectomy in pediatric patients with 
ESRD	due	to	nephrotic	syndrome	in	a	
single-center	study	(2013-2018)
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4  | DISCUSSION
Our	case	series	showed	that	controlled	medical	nephrectomy	in	chil-
dren	with	ESRD	due	 to	nephrotic	 syndrome	 is	 a	 feasible	 and	 safe	
non-invasive	treatment	 in	the	preparation	of	renal	transplantation.	
ACE	 inhibitors	 seem	 to	be	 the	drug	of	 first	 choice	because	of	 the	





since it was only given to one patient in our institution.
Previous case reports evaluating medical nephrectomy observed 
variable	results	(for	an	overview,	see	Table	3).12-14,17,19	In	all	reports,	
ACE	inhibitors,	indomethacin,	or	another	NSAID	were	used	to	achieve	
an acceptable circulatory state before transplantation. Dosages used 






used as an effective method to achieve intravascular volume deple-





tality	 and	 only	minor	morbidity,	mainly	 related	 to	 the	 surgery.	 As	
described,	 2	 patients	were	 already	 treated	with	 anti-hypertensive	
agents,	including	ACE	inhibitors,	and	had	a	surgical	nephrectomy	for	
uncontrolled	 blood	 pressure.	 In	 addition,	 in	 1	 patient	 surgical	 ne-
phrectomy	was	performed	to	stabilize	the	patient	due	to	extensive	
fluid	overload,	in	whom	it	was	deemed	impossible	to	perform	a	med-
ical nephrectomy. These cases illustrate that surgical nephrectomy 
may	be	a	preferred	option,	and	an	individualized	consideration	of	the	
treatment options should be made.
Another	 option	 to	 shut	 down	 the	 kidneys	 is	 by	 bilateral	 renal	
artery	 embolization.	 The	 reported	 success	 rate	 is	 higher	 than	 in	
medical	nephrectomy,	but	side	effects	can	be	severe.11-12,19	Side	ef-




 1 2 3 4 5 6 7 8
Disease CNS CNS CNS FSGS CNS FSGS FSGS CNS
Mutation NPHS2 NPHS2 NPHS1 − NPHS2 − − NPHS1
Gender	(M/F) M F M M M F M F
Age	at	diagnosis 0.8 1.2 0.06 3.0 3.0 3.5 3.7 0.04
Age	at	start	MN	(y) 2.9 4.0 2.3 9.4 4.3 5.4 6.2 4.0
Age	at	KT	(y) 3.4 4.4 4.6 10.0 5.7 6.1 − 6.5
RRT mode PD PD HD HD HD PD HD PD
Enalapril	(mg/kg/d) + + + + + + + +
Initial	dosage 0.07 0.09 0.09 0.08 0.31 0.11 0.10 0.08
Maximum	dosage 0.15 0.40 0.09 0.76 0.37 0.22 0.10 0.08
Indomethacin	(mg/kg/d) − − + − − − − +
Initial	dosage − − 1.15 − − − − 1.01
Maximum	dosage − − 1.15 − − − − 2.02
Diclofenac (mg/kga ) − − − + − − − −
Initial	dosage − − − 1.52 − − − −
Maximum	dosage − − − 3.05 − − − −
Surgical	nephrectomy − − + − − − − +
UO	before	KT Reduced Reduced Anuria Reduced Anuria Reduced Reduced Anuria
Serum	albumin	before	MN	(g/L) 12 19 11 28 24 17 11 19
Serum	albumin	before	KT	(g/L) 30 27 39 33 32 26 − 37
Protein-creatinin	ratio	after	KTb 	
(g/10	mmoL)
0.30 0.42 0.25 3.63 0.33 0.40 NA 0.70
Abbreviations:	CNS,	congenital	nephrotic	syndrome;	FSGS,	focal	segmental	glomerular	sclerosis;	HD,	hemodialysis;	KT,	kidney	transplantation;	MN,	
medical	nephrectomy;	NA,	not	applicable;	PD,	peritoneal	dialysis;	RRT,	renal	replacement	therapy;	UO,	urine	output.
aDosed after each hemodialysis session. 
b9-38	d	after	KT.	
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infusion of local anesthetic.11-12,19 This method seems to be more 
invasive,	especially	in	children,	frequently	needing	general	anesthe-
sia.	In	addition,	an	experienced	physician	is	needed	to	perform	this	
treatment	 and	 there	 is	 a	 risk	of	 injuring	 the	 femoral	 artery,	which	
may hamper arterial anastomosis during kidney transplantation.





output,	 the	 lack	 of	 fixed	 time-points	 to	 measure	 proteinuria	 and	
thereby	 missing	 data	 on	 pretransplant	 proteinuria,	 and	 the	 small	
sample	size.	No	conclusions	can	be	drawn	regarding	 indomethacin	
and	 diclofenac.	 Surprisingly,	 unsuccessful	 medical	 nephrectomy	
seems	to	be	associated	with	having	a	NPHS1	gene	mutation.	Both	
our	patients	with	NPHS1	gene	mutation	did	not	respond	to	medical	





Total (%) 8/8 (100) 2/8	(25.0) 1/8	(12.5)
Urine	output
No	difference 1/8 0/2 0/1
Reduced 6/8 2/2 1/1
Anuria 1/8 0/2 0/1
Albumin	level	(g/L)
Premedicationa  18	(11-28) 25	(21-29) 34











Study Year N Disease Method
Success 
rate (%) Side effects
Medical
Baumelou17 1982 1a  Membranous nephropathy Indomethacin	(150	mg/day) 1/1 —
Hagerty18 1989 1a  Type	1	MPGN Naproxen	(500	mg/day) 1/1 —




Solak13 2010 1a  NS	secondary	to	amyloidosis ACEi	(80	mg/day)	+	indomethacin	
(150	mg/day)
0/1 No	effect
Maeda19 2011 1a  Membranous nephropathy Indomethacin	(max	1000	mg/day) 0/1 No	effect
Sallam12 2012 1a  FSGS NSAID	(high	dose) 0/1 Gastrointestinal





Total  14   9/14	(64.3)  
Embolization
Capozza11 2007 1 Massive proteinuria  1/1 Flank	pain,	(fever)
Solak13 2010 1a  NS	secondary	to	amyloidosis  1/1 —
Maeda19 2011 1a  Membranous nephropathy  1/1 Fever,	elevated	LDH,	
WBC,	CRP
Sallam12 2012 1a  FSGS  1/1 Fever,	flank	pain,	
leukocytosis
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candidates with proteinuria from the native kidneys.
Since	thrombosis	is	an	uncommon	outcome,	it	cannot	be	deter-
mined whether medical nephrectomy decreases the risk of thrombo-
sis	post-transplant.	Prospectively	showing	improvements	in	clotting	
factors	such	as	ATIII	would	be	useful	in	future	studies.	Another	po-
tential pitfall of medical nephrectomy could be the recurrence of 
proteinuria after transplantation. We did not observe any rebound 
proteinuria,	which	may	be	explained	by	the	use	of	tacrolimus	as	part	
of	the	immunosuppressive	regimen,	as	tacrolimus	is	well	known	to	







edge that complications may still occur and patients should be on 
close	 monitoring.	 However,	 these	 data	 suggest	 that	 complications	
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